China is transforming brain-computer interface (BCI) technology from experimental research into clinical reality at a pace that's catching global attention. The country officially included BCI development in its 2026 government work report, and companies are securing regulatory approvals and raising record-breaking funding rounds. This shift signals that the race to commercialize brain-machine communication is no longer dominated by a single player like Elon Musk's Neuralink .

What's Actually Happening in China's BCI Clinics Right Now?

At the Second Affiliated Hospital of Chongqing Medical University, stroke patients are already using BCI technology for rehabilitation. One patient, identified as Mr. Wang, experienced weakness in his left leg after a stroke. After undergoing BCI-powered rehabilitation training, he reported feeling "more relaxed" and noticing improved strength when walking . The technology works by reading brainwaves through wearable devices, interpreting the brain's intentions, and translating those signals into commands that help patients move their limbs without active physical effort.

"The system first reads brain information, primarily brainwaves, alongside other neural data. It then interprets the meaning of these signals through post-processing and ultimately connects them to a machine. This is the core logic of a BCI," explained Chen Yangmei, Director of Neurology at the Second Affiliated Hospital of Chongqing Medical University.

Chen Yangmei, Director of Neurology at the Second Affiliated Hospital of Chongqing Medical University

These aren't theoretical applications. Patients with neurological conditions like stroke sequelae and Parkinson's disease are actively using BCIs to improve limb function and quality of life . The technology comes in two main forms: non-invasive systems using wearable devices, and invasive systems that surgically implant electrodes directly into the brain. The key difference is signal precision, with invasive methods offering higher accuracy but requiring surgery .

How Are Chinese Companies Funding This Technology Boom?

The investment momentum is staggering. Neuracle Medical Technology just secured China's first-ever approval for an implantable BCI system designed to restore hand motor function in spinal cord injury patients. The company's coin-sized wireless device sits on the brain's outer surface without penetrating tissue, reading neural signals and translating them into hand movements . This approval marked the first time globally that an invasive BCI could be sold and used on patients as a commercial product .

Meanwhile, a startup called Gestala raised $21.6 million just two months after launching, at a valuation between $100 million and $200 million. The round was heavily oversubscribed, with investor commitments totaling more than $58 million, making it the largest early-stage funding in China's BCI industry . Gestala is developing non-invasive ultrasound-based BCIs, which founder Phoenix Peng believes could represent the next generation of brain-computer interface technology.

"Non-invasive ultrasound could address one of the biggest barriers to BCI adoption: the risks associated with brain surgery. Compared with implanted electrode systems, the technology can monitor a larger portion of the brain, including deep neural circuits," Peng explained.

Phoenix Peng, Founder and CEO of Gestala

Gestala plans to use its funding toward research and development, expanding its team from 15 to approximately 35 employees by year-end, and building a manufacturing facility in China . The company aims to complete its first-generation prototype by the end of 2026.

Why Should You Care About the Global BCI Market Size?

The numbers reveal why companies and governments are investing so heavily. The global BCI market was valued at $2.94 billion in 2025 and is projected to grow to $3.33 billion in 2026. By 2035, it's expected to reach approximately $13.86 billion, representing a compound annual growth rate of 16.77% from 2026 to 2035 . Another market analysis projects even higher growth, with the market reaching $14.87 billion by 2035 at a compound annual growth rate of 15.83% .

This explosive growth is driven by a massive patient population. The World Health Organization's 2025 Global Status Report on Neurology indicates that neurological disorders affect over 40% of the global population, with more than 3 billion people suffering from these conditions and over 11 million deaths annually . That's a clinical demand signal that's hard to ignore.

Steps to Understanding BCI Technology's Current State

• Non-Invasive BCIs Dominate: Over 83% of the current market consists of non-invasive BCIs that don't require surgery, using wearable devices to achieve therapeutic effects safely and accessibly .
• AI Integration Is Accelerating: Machine learning is enabling real-time brain signal processing, improving accuracy and usability in applications ranging from neuroprosthetics to gaming .
• Clinical Applications Are Expanding: BCIs are moving beyond stroke rehabilitation into chronic pain management, mental health conditions including depression and PTSD, and longer-term targets like Alzheimer's disease and Parkinson's disease .
• Manufacturing Speed Matters: Chinese companies are leveraging integrated manufacturing ecosystems to move from development to production faster than international competitors, with clinical trials costing roughly 20% to 33% of comparable studies in the U.S. or Europe .

What Technical Challenges Still Need Solving?

Despite the rapid progress, significant hurdles remain. Interpreting signals after flexible electrodes are implanted in the brain, improving brain signal decoding technology, and advancing computing power and software optimization all require further development . Battery life and long-term usability of wearable BCI devices remain limitations, and the technical complexity of accurately interpreting brain signals in real-time continues to challenge researchers .

Ethical and privacy concerns also loom large. The ability to read and interpret brain signals raises fundamental questions about data privacy and ethical usage that regulators and companies are still grappling with . High development and deployment costs remain a barrier, as BCI systems require advanced hardware, software, and extensive research .

Yet the momentum is undeniable. Neuralink announced it will begin mass-producing BCI devices in 2026, backed by $650 million in Series E funding completed in 2025, and the company is advancing a highly simplified, nearly fully automated surgical process to lower the trauma threshold of invasive procedures . Chinese competitors are moving at comparable speed, suggesting the BCI market is transitioning from research phase to commercial reality faster than many observers expected.